Publicaciones en colaboración con investigadores/as de Hospital del Mar (12)

2022

  1. Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

    European Journal of Surgical Oncology, Vol. 48, Núm. 5, pp. 1123-1132

2020

  1. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected

    Clinical Colorectal Cancer, Vol. 19, Núm. 3, pp. e110-e116

2018

  1. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

    British Journal of Cancer, Vol. 119, Núm. 12, pp. 1464-1470

2016

  1. Quality indicators to assure and improve cancer care in Spain using the delphi technique

    JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, Núm. 5, pp. 553-558

2012

  1. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A spanish cooperative group for the treatment of digestive tumors study

    Oncologist, Vol. 17, Núm. 7, pp. 947-955

  2. First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Onkologie, Vol. 6, Núm. 2, pp. 96-103

  3. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study

    Oncologist, Vol. 17, Núm. 1, pp. 15-25

  4. Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

    PLoS ONE, Vol. 7, Núm. 10

2003

  1. Irinotecan (CPT-11) in Metastatic Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU): A Phase II Study

    Methods and Findings in Experimental and Clinical Pharmacology, Vol. 25, Núm. 8, pp. 639-643

2002

  1. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

    Cancer, Vol. 95, Núm. 4, pp. 751-757

2000

  1. Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 2, Núm. 3, pp. 154-158

1999

  1. UFT Plus or Minus Calcium Folinate for Metastatic Golorectal Cancer in Older Patients

    ONCOLOGY, Vol. 13, Núm. 7 SUPPL., pp. 35-40